SMNH Technology
The “SMNH” technology platform enables us to create rationally designed drug candidates using known structural information on validated, disease associated targets. SMNH compounds incorporate unique chemical features that enable selective interaction with the intended target and confer desirable pharmaceutical properties, like oral bioavailability and favorable pharmacokinetics. SMNH compounds can be designed to interact specifically and selectively with a broad range of targets including, nucleic and binding sites, one of the most common structural motifs on proteins, as well as DNA or RNA molecules. Hence, it can be applied across an array of therapeutic indications.
To discover new drug candidates, we synthesize focused libraries of SMNH molecules guided by 3D structures of the intended target(s) and then screen these compounds using in vitro assays and animal models to identify optimal structures for further development.
About Hepatitis
Over 350 million people are chronically infected with HBV virus worldwide. The HBV virus is a DNA virus which incorporates into the hepatocyte DNA. Read More >>
Approximately 170 million people worldwide and 4 million in the United States are infected with HCV. HCV infection is one of the most significant public health threats facing Americans.
Read More >>
